Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer.
Alice IlariViola CogliatiNoorhan SherifEmanuela GrassilliDaniele RamazzottiNicoletta CordaniGiorgio CazzanigaCamillo Di BellaMaria Luisa LavitranoMarina Elena CazzanigaMaria Grazia CerritoPublished in: Biomedicines (2024)
A group of 27 patients diagnosed with metastatic triple-negative breast cancer (mTNBC) was randomly distributed into two groups and underwent different lines of metronomic treatment (mCHT). The former group (N 14) received first-line mCHT and showed a higher overall survival rate than the second group (N 13), which underwent second-line mCHT. Analysis of one patient still alive from the first group, diagnosed with mTNBC in 2019, showed a complete metabolic response (CMR) after a composite approach implicating first-line mCHT followed by second-line epirubicin and third-line nab-paclitaxel, and was chosen for subsequent molecular characterization. We found altered expression in the cancer stemness-associated gene NOTCH-1 and its corresponding protein. Additionally, we found changes in the expression of oncogenes, such as MYC and AKT , along with their respective proteins. Overall, our data suggest that a first-line treatment with mCHT followed by MTD might be effective by negatively regulating stemness traits usually associated with the emergence of drug resistance.
Keyphrases
- stem cells
- cell proliferation
- end stage renal disease
- epithelial mesenchymal transition
- case report
- small cell lung cancer
- squamous cell carcinoma
- genome wide
- ejection fraction
- newly diagnosed
- chronic kidney disease
- signaling pathway
- gene expression
- transcription factor
- electronic health record
- mesenchymal stem cells
- machine learning
- small molecule
- patient reported
- free survival